`Case 1:24-cv-00053-TSK Document 20-5 Filed 07/03/24 Page 1of 4 PagelD #: 2769
`
`EXHIBIT 5
`EXHIBIT 5
`
`
`
`Case 1:24-cv-00053-TSK Document 20-5 Filed 07/03/24 Page 2 of 4 PageID #: 2770
`
`From:
`To:
`
`Cc:
`Subject:
`Date:
`
`Brett A. Postal
`Beazley, Jennalee; Jennifer Nock; ahardestyodell@bowlesrice.com; mgb-amgen-abp938@marshallip.com;
`kmckitrick@bowlesrice.com; ABP938; jlabbe@marshallip.com
`eylea.biosimilars@weil.com; Eylea; REGENERONPATENT@lists.kellogghansen.com
`RE: Regeneron v. Amgen - 6.12.2024 Production
`Friday, June 21, 2024 10:37:41 AM
`
`Dear Jennalee:
`
`In your email of June 13, 2024, you indicated that Regeneron would be producing the documents
`that Celltrion, Formycon, and Samsung Bioepis provided to you last Wednesday, June 12 no later
`than early this week. On our meet and confer last week, your colleague, Mr. Gregory, confirmed
`that the documents would be produced no later than early this week. It is now Friday and we have
`not received the documents. Please produce them immediately, no later than 5pm today.
`
`Additionally, we note that a redacted version of the Order in the Mylan/Biocon case was publicly
`filed this morning (No. 24-md-3103, Dkt. 188). Please provide us with a copy of the Order with only
`Mylan/Biocon confidential information redacted no later than Monday, June 24.
`
`Best regards,
`Brett
`
`
`
`Brett A. Postal
`901 New York Avenue, NW
`Suite 900 East
`Washington, D.C. 20001
`
`Main Number: 202.783.6040
`Fax Number: 202.783.6031
`Email: bpostal@rothwellfigg.com
`Website: www.rothwellfigg.com
`
`The information contained in this electronic message and any attachments to this message are intended for the exclusive use of the
`addressee(s) and may contain confidential and/or privileged information. If you are not the addressee, note that any disclosure, copy,
`distribution or use of the contents of this message is prohibited. If you are not the intended recipient, please notify Rothwell, Figg, Ernst &
`Manbeck, P.C. immediately at (202) 783-6040 or email us at bpostal@rfem.com, and destroy all copies of this message and any
`attachments.
`
`From: Beazley, Jennalee <jbeazley@wc.com>
`Sent: Thursday, June 13, 2024 9:35 AM
`To: Brett A. Postal <bpostal@rothwellfigg.com>; Jennifer Nock <jnock@rothwellfigg.com>;
`ahardestyodell@bowlesrice.com; mgb-amgen-abp938@marshallip.com;
`kmckitrick@bowlesrice.com; ABP938 <ABP938@rothwellfigg.com>; jlabbe@marshallip.com
`Cc: eylea.biosimilars@weil.com; Eylea <Eylea@wc.com>;
`REGENERONPATENT@lists.kellogghansen.com
`Subject: RE: Regeneron v. Amgen - 6.12.2024 Production
`
`Dear Brett,
`
`
`
`Case 1:24-cv-00053-TSK Document 20-5 Filed 07/03/24 Page 3 of 4 PageID #: 2771
`
`
`Mylan’s Opposition Brief is currently being prepared by our vendor to be produced. We expect to
`produce the document either tonight or tomorrow morning.
`
`We are in receipt of Defendants’ additional redacted documents provided to Regeneron late
`yesterday afternoon. We are reviewing and processing them and anticipate being able to produce
`them either late tomorrow or early next week.
`
`
`Best,
`Jennalee
`
`
`
`Jennalee Beazley
`Associate | Williams & Connolly LLP
`680 Maine Avenue, S.W., Washington, DC 20024
`202-434-5767 | jbeazley@wc.com | www.wc.com
`She, Her, Hers
`
`
`From: Brett A. Postal <bpostal@rothwellfigg.com>
`Sent: Wednesday, June 12, 2024 9:09 PM
`To: Beazley, Jennalee <jbeazley@wc.com>; Jennifer Nock <jnock@rothwellfigg.com>;
`ahardestyodell@bowlesrice.com; mgb-amgen-abp938@marshallip.com;
`kmckitrick@bowlesrice.com; ABP938 <ABP938@rothwellfigg.com>; jlabbe@marshallip.com
`Cc: eylea.biosimilars@weil.com; Eylea <Eylea@wc.com>;
`REGENERONPATENT@lists.kellogghansen.com
`Subject: RE: Regeneron v. Amgen - 6.12.2024 Production
`
`Dear Jennalee,
`
`We have reviewed Regeneron’s production from this evening, and Regeneron has not produced
`Mylan’s Opposition Brief from the permanent injunction proceeding. Mylan confirmed that the
`version that was provided to you on March 29, 2024 could be produced. See Email from N.
`McLaughlin of June 11, 2024. Please confirm by noon ET tomorrow (6/13) that it will be produced
`immediately (no later than June 13, 2024).
`
`Please also confirm by noon tomorrow that Regeneron will be producing the additional documents
`that were provided by Celltrion, Samsung, and Formycon by the end of the week.
`
`Best regards,
`Brett
`
`
`
`
`Case 1:24-cv-00053-TSK Document 20-5 Filed 07/03/24 Page 4 of 4 PageID #: 2772
`
`
`Brett A. Postal
`901 New York Avenue, NW
`Suite 900 East
`Washington, D.C. 20001
`
`Main Number: 202.783.6040
`Fax Number: 202.783.6031
`Email: bpostal@rothwellfigg.com
`Website: www.rothwellfigg.com
`
`The information contained in this electronic message and any attachments to this message are intended for the exclusive use of the
`addressee(s) and may contain confidential and/or privileged information. If you are not the addressee, note that any disclosure, copy,
`distribution or use of the contents of this message is prohibited. If you are not the intended recipient, please notify Rothwell, Figg, Ernst &
`Manbeck, P.C. immediately at (202) 783-6040 or email us at bpostal@rfem.com, and destroy all copies of this message and any
`attachments.
`
`From: Beazley, Jennalee <jbeazley@wc.com>
`Sent: Wednesday, June 12, 2024 4:46 PM
`To: Jennifer Nock <jnock@rothwellfigg.com>; Brett A. Postal <bpostal@rothwellfigg.com>;
`ahardestyodell@bowlesrice.com; mgb-amgen-abp938@marshallip.com;
`kmckitrick@bowlesrice.com; ABP938 <ABP938@rothwellfigg.com>; jlabbe@marshallip.com
`Cc: eylea.biosimilars@weil.com; Eylea <Eylea@wc.com>;
`REGENERONPATENT@lists.kellogghansen.com
`Subject: Regeneron v. Amgen - 6.12.2024 Production
`
`Counsel,
`
`Please see the attached production correspondence.
`
`Best,
`Jennalee
`
`Jennalee Beazley
`Associate | Williams & Connolly LLP
`680 Maine Avenue, S.W., Washington, DC 20024
`202-434-5767 | jbeazley@wc.com | www.wc.com
`She, Her, Hers
`
`
`
`
`This message and any attachments are intended only for the addressee and may contain information that is
`privileged and confidential. If you have received this message in error, please do not read, use, copy, distribute, or
`disclose the contents of the message and any attachments. Instead, please delete the message and any attachments
`and notify the sender immediately. Thank you.
`
`